Lactoferrin and Natural Killer Cells: Activation and Cancer Surveillance

Expert Summary

NK cells recognize and kill cancer cells and virus-infected cells without prior sensitization — making them the frontline defense against cancer and viral infection. Lactoferrin binds to NK cell LfR1 receptors and activates intracellular STAT4 signaling, increasing NK cell cytotoxic granule content (granzyme B, perforin) and ADCC (antibody-dependent cellular cytotoxicity) capacity.

Key Facts

• LfR1 on NK cells: Lactoferrin receptor 1 is expressed on NK cells, monocytes, and activated lymphocytes. LfR1 binding by lactoferrin triggers phospholipase C activation → IP3 → calcium release → NK cell degranulation (cytotoxic granule release).
• Cytotoxicity enhancement: In controlled cell culture experiments, lactoferrin treatment (10–100 μg/mL) enhances NK cell lysis of target cancer cells (K562, Jurkat, HeLa) by 1.5–3-fold at effector:target ratios used in clinical cytotoxicity assays.
• Granzyme B and perforin: NK cells kill target cells by releasing granzyme B (serine protease) and perforin (pore-forming protein) from granules. Lactoferrin treatment significantly increases NK cell granule content of both — the molecular basis of enhanced cytotoxicity.
• ADCC amplification: Antibody-dependent cellular cytotoxicity (ADCC) — NK cell killing of antibody-coated targets — is significantly enhanced by lactoferrin. This is particularly relevant for cancer immunotherapy applications (ADCC is the mechanism of therapeutic antibodies like trastuzumab for breast cancer).
• Cancer prevention rationale: The NK immune surveillance hypothesis proposes that initial cancer cells are recognized and eliminated by NK cells before clinical disease develops. Declining NK function with aging impairs this surveillance, allowing cancer to establish. Restoring NK function via lactoferrin could theoretically improve cancer prevention.
• Human evidence: Lactoferrin supplementation in immunocompromised patients (post-surgery, chemotherapy recovery) shows measurable NK activity restoration — clinically relevant for improving outcomes in these vulnerable populations.

Recommended Products

Frequently Asked Questions

Does lactoferrin have cancer treatment applications?

Lactoferrin is not a cancer treatment. Its NK cell activation and ADCC enhancement properties are relevant for immune surveillance (prevention), and some researchers have proposed lactoferrin as an adjunct to cancer immunotherapy. No clinical trials have established lactoferrin as primary or adjunct cancer treatment.

How often should I take lactoferrin for cancer prevention purposes?

Daily continuous use (200–300 mg/day) is most appropriate for sustained NK cell activation support. Cancer immune surveillance is a continuous process requiring ongoing immune vigilance.

Scientific References

• Berlutti F et al. Antiviral properties of lactoferrin. Molecules. 2011. PMID: 21847071